ARQT · Arcutis Biotherapeutics Inc
United States · RS rating 95 · As of 2026-11-03
| Price | 32.00 USD |
|---|---|
| 1-day change | +2.4% |
| RS rating (overall / 1M / 3M / 12M) | 95 / 96 / 88 / 73 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 59 / 50 / 70 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +116.7% |
| Sales growth Q/Q | +30.5% |
| Distance from 52-week high | +2.5% |
| Market cap (USD) | $2.9B |